[en] BACKGROUND AND PURPOSE: Lymphangiogenesis is an important biological process associated with the pathogenesis of several diseases, including metastatic dissemination, graft rejection, lymphedema and other inflammatory disorders. The development of new drugs blocking lymphangiogenesis has become a promising therapeutic strategy. In this study, we aim at investigating the ability of toluquinol, a 2-methyl-hydroquinone isolated from the culture broth of the marine fungus Penicillium sp. HL-85-ALS5-R004, to inhibit lymphangiogenesis in vitro, ex vivo and in vivo. EXPERIMENTAL APPROACH: We used human lymphatic endothelial cells (LEC) to analyze the effect of toluquinol in 2D and 3D in vitro cultures, and in the ex vivo mouse lymphatic ring assay. For in vivo approaches, the transgenic Fli1:eGFPy1 zebrafish, the mouse ear sponges and cornea models were used. Western-blotting and apoptosis analyses were carried out to search for drug targets. KEY RESULTS: Toluquinol inhibited LEC proliferation, migration, tubulogenesis and sprouting of new lymphatic vessels. Furthermore, toluquinol induced LEC apoptosis after 14 h of treatment in vitro, blocked the thoracic duct development in zebrafish, and reduced the VEGF-C-induced lymphatic vessel formation and corneal neovascularization in mice. Mechanistically, we are providing evidence that this drug abrogates the VEGF-C-induced VEGFR-3 phosphorylation in a dose-dependent manner, and represses Akt and ERK1/2 phosphorylations. CONCLUSIONS AND IMPLICATIONS: Based on these findings, we propose toluquinol as a new candidate with pharmacological potential for the treatment of lymphangiogenesis-related pathologies. Notably, its ability to suppress corneal neovascularization paves the way for applications in vascular ocular pathologies. This article is protected by copyright. All rights reserved.
Disciplines :
Biochemistry, biophysics & molecular biology
Author, co-author :
Garcia-Caballero, Melissa
Blacher, Silvia ; Centre Hospitalier Universitaire de Liège - CHU > Centre d'oncologie
Abdelfattah NS, Amgad M, Zayed AA, Salem H, Elkhanany AE, Hussein H, et al., (2015). Clinical correlates of common corneal neovascular diseases: a literature review. Int J Ophthalmol 8: 182-193.
Alexander SPH, Fabbro D, Kelly E, Marrion N, Peters JA, Benson HE, et al., (2015a). The Concise Guide to PHARMACOLOGY 2015/16: Catalytic receptors. Br J Pharmacol 172: 5979-6023.
Alexander SPH, Fabbro D, Kelly E, Marrion N, Peters JA, Benson HE, et al., (2015b). The Concise Guide to PHARMACOLOGY 2015/16: Enzymes. Br J Pharmacol 172: 6024-6109.
Alitalo A, Detmar M, (2012). Interaction of tumor cells and lymphatic vessels in cancer progression. Oncogene 31: 4499-4508.
Alitalo K, (2011). The lymphatic vasculature in disease. Nat Med 17: 1371-1380.
Amadio M, Govoni S, Pascale A, (2016). Targeting VEGF in eye neovascularization: what's new?: a comprehensive review on current therapies and oligonucleotide-based interventions under development. Pharmacol Res 103: 253-269.
Astin JW, Jamieson SM, Eng TC, Flores MV, Misa JP, Chien A, et al., (2014). An in vivo antilymphatic screen in zebrafish identifies novel inhibitors of mammalian lymphangiogenesis and lymphatic-mediated metastasis. Mol Cancer Ther 13: 2450-2462.
Aspelund A, Robciuc MR, Karaman S, Makinen T, Alitalo K, (2016). Lymphatic system in cardiovascular medicine. Circ Res 118: 515-530.
Bachmann B, Taylor RS, Cursiefen C, (2010). Corneal neovascularization as a risk factor for graft failure and rejection after keratoplasty: an evidence-based meta-analysis. Ophthalmology 117: 1300-1305.
Bahram F, Claesson-Welsh L, (2010). VEGF-mediated signal transduction in lymphatic endothelial cells. Pathophysiology 17: 253-261.
Bhatnagar I, Kim SK, (2010). Immense essence of excellence: marine microbial bioactive compounds. Mar Drugs 8: 2673-2701.
Blacher S, Erpicum C, Lenoir B, Paupert J, Moraes G, Ormenese S, et al., (2014). Cell invasion in the spheroid sprouting assay: a spatial organisation analysis adaptable to cell behaviour. PLoS One 9: e97019.
Bock F, Maruyama K, Regenfuss B, Hos D, Steven P, Heindl LM, et al., (2013). Novel anti(lymph)angiogenic treatment strategies for corneal and ocular surface diseases. Prog Retin Eye Res 34: 89-124.
Bruyère F, Melen-Lamalle L, Blacher S, Roland G, Thiry M, Moons L, et al., (2008). Modeling lymphangiogenesis in a three-dimensional culture system. Nat Methods 5: 431-437.
Coso S, Bovay E, Petrova TV, (2014). Pressing the right buttons: signaling in lymphangiogenesis. Blood 123: 2614-2624.
Curtis MJ, Bond RA, Spina D, Ahluwalia A, Alexander SP, Giembycz MA, et al., (2015). Experimental design and analysis and their reporting: new guidance for publication in BJP. Br J Pharmacol 172: 3461-3471.
Deng Y, Zhang X, Simons M, (2015). Molecular controls of lymphatic VEGFR3 signaling. Arterioscler Thromb Vasc Biol 35: 421-429.
Detry B, Erpicum C, Paupert J, Blacher S, Maillard C, Bruyère F, et al., (2012). Matrix metalloproteinase-2 governs lymphatic vessel formation as an interstitial collagenase. Blood 119: 5048-5056.
García-Caballero M, Marí Beffa M, Cañedo L, Medina MA, Quesada AR, (2013). Toluquinol, a marine fungus metabolite, is a new angiosuppresor that interferes the Akt pathway. Biochem Pharmacol 85: 1727-1740.
Hos D, Schlereth SL, Bock F, Heindl LM, Cursiefen C, (2014). Antilymphangiogenic therapy to promote transplant survival and to reduce cancer metastasis: what can we learn from the eye? Semin Cell Dev Biol 38: 117-130.
Hu J, Ye H, Fu A, Chen X, Wang Y, Chen X, et al., (2010). Deguelin-an inhibitor to tumor lymphangiogenesis and lymphatic metastasis by downregulation of vascular endothelial cell growth factor-D in lung tumor model. Int J Cancer 127: 2455-2466.
Iwata C, Kano MR, Komuro A, Oka M, Kiyono K, Johansson E, et al., (2007). Inhibition of cyclooxygenase-2 suppresses lymph node metastasis via reduction of lymphangiogenesis. Cancer Res 67: 10181-10189.
Karaman S, Detmar M, (2014). Mechanisms of lymphatic metastasis. J Clin Invest 124: 922-928.
Khazir J, Riley DL, Pilcher LA, De-Maayer P, Mir BA, (2014). Anticancer agents from diverse natural sources. Nat Prod Commun 9: 1655-1669.
Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
Lenoir B, Wagner DR, Blacher S, Sala-Newby GB, Newby AC, Noel A, et al., (2014). Effects of adenosine on lymphangiogenesis. PLoS One 9: e92715.
Liang CC, Park AY, Guan JL, (2007). In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc 2: 329-333.
Liu ZY, Qiu HO, Yuan XJ, Ni YY, Sun JJ, Jing W, et al., (2012). Suppression of lymphangiogenesis in human lymphatic endothelial cells by simultaneously blocking VEGF-C and VEGF-D/VEGFR-3 with norcantharidin. Int J Oncol 41: 1762-1772.
Lohela M, Saaristo A, Veikkola T, Alitalo K, (2003). Lymphangiogenic growth factors, receptors and therapies. Thromb Haemost 90: 167-184.
Lohela M, Bry M, Tammela T, Alitalo K, (2009). VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Curr Opin Cell Biol 21: 154-165.
Mäkinen T, Veikkola T, Mustjoki S, Karpanen T, Catimel B, Nice EC, et al., (2001). Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3. EMBO J 20: 4762-4773.
Matsumoto G, Yajima N, Saito H, Nakagami H, Omi Y, Lee U, et al., (2010). Cold shock domain protein A (CSDA) overexpression inhibits tumor growth and lymph node metastasis in a mouse model of squamous cell carcinoma. Clin Exp Metastasis 27: 539-547.
McGrath JC, Lilley E, (2015). Implementing guidelines on reporting research using animals (ARRIVE etc.): new requirements for publication in BJP. Br J Pharmacol 172: 3189-3193.
McGrath JC, McLachlan EM, Zeller R, (2015). Transparency in research involving animals: the Basel declaration and new principles for reporting research in BJP manuscripts. Br J Pharmacol 172: 2427-2432.
Nakamura ES, Koizumi K, Kobayashi M, Saiki I, (2004). Inhibition of lymphangiogenesis-related properties of murine lymphatic endothelial cells and lymph node metastasis of lung cancer by the matrix metalloproteinase inhibitor MMI270. Cancer Sci 95: 25-31.
Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L, (2006). VEGF receptor signaling? In control of vascular function. Nat Rev Mol Cell Biol 7: 359-371.
Paupert J, Sounni NE, Noël A, (2011). Lymphangiogenesis in post-natal tissue remodeling: lymphatic endothelial cell connection with its environment. Mol Aspects Med 32: 146-158.
Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al., NC-IUPHAR(2014). The IUPHAR/BPS guide to PHARMACOLOGY: an expert-driven knowledge base of drug targets and their ligands. Nucleic Acids Res 42: D1098-D1106.
Quagliata L, Klusmeier S, Cremers N, Pytowski B, Harvey A, Pettis RJ, et al., (2014). Inhibition of VEGFR-3 activation in tumor-draining lymph nodes suppresses the outgrowth of lymph node metastases in the MT-450 syngeneic rat breast cancer model. Clin Exp Metastasis 31: 351-365.
Schulte-Merker S, Sabine A, Petrova TV, (2011). Lymphatic vascular morphogenesis in development, physiology, and disease. J Cell Biol 193: 607-618.
Senthilkumar K, Venkatesan J, Manivasagan P, Kim SK, (2013). Antiangiogenic effects of marine sponge derived compounds on cancer. Environ Toxicol Pharmacol 36: 1097-1108.
Sleeman JP, Thiele W, (2009). Tumor metastasis and the lymphatic vasculature. Int J Cancer 125: 2747-2756.
Varricchi G, Granata F, Loffredo S, Genovese A, Marone G, (2015). Angiogenesis and lymphangiogenesis in inflammatory skin disorders. J Am Acad Dermatol 73: 144-153.
Wen J, Fu AF, Chen LJ, Xie XJ, Yang GL, Chen XC, et al., (2009). Liposomal honokiol inhibits VEGF-D-induced lymphangiogenesis and metastasis in xenograft tumor model. Int J Cancer 124: 2709-2718.
Witte MH, Dellinger MT, McDonald DM, Nathanson SD, Boccardo FM, Campisi CC, et al., (2011). Lymphangiogenesis and hemangiogenesis: potential targets for therapy. J Surg Oncol 103: 489-500.
Yashiro M, Shinto O, Nakamura K, Tendo M, Matsuoka T, Matsuzaki T, et al., (2009). Effects of VEGFR-3 phosphorylation inhibitor on lymph node metastasis in an orthotopic diffuse-type gastric carcinoma model. Br J Cancer 101: 1100-1106.
Zhang L, Zhou F, Han W, Shen B, Luo J, Shibuya M, et al., (2010). VEGFR-3 ligand-binding and kinase activity are required for lymphangiogenesis but not for angiogenesis. Cell Res 20: 1319-1331.
Zhang XY, Lu WY, (2014). Recent advances in lymphatic targeted drug delivery system for tumor metastasis. Cancer Biol Med 11: 247-254.
Zheng W, Aspelund A, Alitalo K, (2014). Lymphangiogenic factors, mechanisms, and applications. J Clin Invest 124: 878-887.
Zwaans BM, Bielenberg DR, (2007). Potential therapeutic strategies for lymphatic metastasis. Microvasc Res 74: 145-158.